Pan Shing Yi, Chia Yvonne Cashinn, Yee Hui Rong, Fang Cheng Angelina Ying, Anjum Clarice Evey, Kenisi Yenny, Chan Mike Ks, Wong Michelle Bf
FCTI Biotech R&D GmbH Klosterstrasse 205, 67480 Edenkoben, Germany.
Baden R&D Laboratories GmbH Klosterstrasse 205, 67480 Edenkoben, Germany.
Future Sci OA. 2020 Oct 29;7(2):FSO648. doi: 10.2144/fsoa-2020-0142.
The immune system is a complex network of specialized cells and organs that recognises and reacts against foreign pathogens while remaining unresponsive to host tissues. This ability to self-tolerate is known as immunological tolerance. Autoimmune disease occurs when the immune system fails to differentiate between self and non-self antigens and releases autoantibodies to attack our own cells. Anti-idiotypic (anti-ID) antibodies are important in maintaining a balanced idiotypic regulatory network by neutralising and inhibiting the secretion of autoantibodies. Recently, anti-ID antibodies have been advanced as an alternative form of immunotherapy as they can specifically target autoantibodies, cause less toxicity and side effects, and could provide long-lasting immunity. This review article discusses the immunomodulatory potential of anti-ID antibodies for the treatment of autoimmune diseases.
免疫系统是一个由特殊细胞和器官组成的复杂网络，它能识别外来病原体并做出反应，同时对宿主组织无反应。这种自我耐受的能力被称为免疫耐受。当免疫系统无法区分自身和非自身抗原并释放自身抗体来攻击我们自己的细胞时，自身免疫性疾病就会发生。抗独特型（抗Id）抗体通过中和和抑制自身抗体的分泌，在维持平衡的独特型调节网络中起重要作用。最近，抗Id抗体已被视为一种免疫治疗的替代形式，因为它们可以特异性地靶向自身抗体，产生较少的毒性和副作用，并能提供持久的免疫力。这篇综述文章讨论了抗Id抗体在治疗自身免疫性疾病方面的免疫调节潜力。
